{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:58:11Z","timestamp":1763755091216,"version":"3.45.0"},"reference-count":26,"publisher":"Oncology Nursing Society (ONS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2007,12,1]]},"DOI":"10.1188\/07.cjon.847-851","type":"journal-article","created":{"date-parts":[[2007,12,13]],"date-time":"2007-12-13T08:25:48Z","timestamp":1197534348000},"page":"847-851","source":"Crossref","is-referenced-by-count":5,"title":["Multiple Myeloma and Treatment-Related Thromboembolism: Oncology Nurses' Role in Prevention, Assessment, and Diagnosis"],"prefix":"10.1188","volume":"11","author":[{"given":"Kathleen E.","family":"Wiley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,12,6]]},"reference":[{"unstructured":"American Cancer Society. (2007). Overview multiple myeloma: How many people get multiple myeloma? Retrieved November 4, 2007, from <a target=\"_blank\" href='http:\/\/www.cancer.org\/docroot\/CRI\/content\/CRI_2_2_1x_How_Many_People_Get_Multiple_Myeloma.asp?sitearea='>http:\/\/www.cancer.org\/docroot\/CRI\/content\/CRI_2_2_1x_How_Many_People_Get_Multiple_Myeloma.asp?sitearea=<\/a>","key":"E00001"},{"doi-asserted-by":"crossref","unstructured":"Anderson, K.C. (2007). Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. <i>Experimental Hematology<\/i>, <b>35<\/b>(4, Suppl. 1), 155-162.","key":"E00002","DOI":"10.1016\/j.exphem.2007.01.024"},{"doi-asserted-by":"crossref","unstructured":"Barber, F.D. (2006). Multiple myeloma: Early recognition by primary care nurse practitioners. <i>Journal for Nurse Practitioners<\/i>, <b>2<\/b>, 665-673.","key":"E00003","DOI":"10.1016\/j.nurpra.2006.08.017"},{"doi-asserted-by":"crossref","unstructured":"Baz, R., Li, L., Kottke-Marchant, K., Srkalovic, G., McGowan, B., Yiannaki, E., et al. (2005). The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracyclinebased chemotherapy for multiple myeloma. <i>Mayo Clinic Proceedings<\/i>, <b>80<\/b>, 1568-1574.","key":"E00004","DOI":"10.4065\/80.12.1568"},{"doi-asserted-by":"crossref","unstructured":"Blann, A.D., & Lip, G.Y. (2006). Venous thromboembolism. <i>BMJ<\/i>, <b>332<\/b>, 215-219.","key":"E00005","DOI":"10.1136\/bmj.332.7535.215"},{"doi-asserted-by":"crossref","unstructured":"Bruno, B., Rotta, M., Giaccone, L., Massaia, M., Bertola, A., Palumbo, A., et al. (2004). New drugs for treatment of multiple myeloma. <i>Lancet Oncology<\/i>, <b>5<\/b>, 430-442.","key":"E00006","DOI":"10.1016\/S1470-2045(04)01511-6"},{"doi-asserted-by":"crossref","unstructured":"Cavo, M., & Baccarani, M. (2006). The changing landscape of myeloma therapy. <i>New England Journal of Medicine<\/i>, <b>354<\/b>, 1076-1078.","key":"E00007","DOI":"10.1056\/NEJMe058322"},{"unstructured":"Celgene Corporation. (2006). Revlimid\u00ae (lenalidomide) [Package insert]. Retrieved March 24, 2007, from <a target=\"_blank\" href='http:\/\/www.celgene.com\/PDF\/RevlimidPI.pdf'>http:\/\/www.celgene.com\/PDF\/RevlimidPI.pdf<\/a>","key":"E00008"},{"doi-asserted-by":"crossref","unstructured":"Zangari, M., Siegel, E., Barlogie, B., Anaissie, E., Saghafifar, F., Athanasios, F., et al. (2002). Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide. <i>Blood<\/i>, <b>100<\/b>, 1168-1171.","key":"E00009","DOI":"10.1182\/blood-2002-01-0335"},{"doi-asserted-by":"crossref","unstructured":"Zierler, B.K. (2004). Ultrasonography and diagnosis of venous thromboembolism. <i>Circulation<\/i>, <b>109<\/b>(12, Suppl. 1), I9-I14.","key":"E00010","DOI":"10.1161\/01.CIR.0000122870.22669.4a"},{"doi-asserted-by":"crossref","unstructured":"Zonder, J.A., Barlogie, B., Durie, B.G.M., McCoy, J., Crowley, J., & Hussein, M.A. (2006). Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: Benefit of aspirin prophylaxis [Letter to the editor]. <i>Blood<\/i>, <b>108<\/b>, 403.","key":"E00011","DOI":"10.1182\/blood-2006-01-0154"},{"unstructured":"Davies, M.J. (2006). Advancing access to myeloma treatment: Administration, side effects, and implications for survival. <i>ONS News<\/i>, <b>21<\/b>(8, Suppl. 1), 11-12.","key":"E00012"},{"doi-asserted-by":"crossref","unstructured":"Devenney, B., & Erikson, C. (2004). Multiple myeloma: An overview. <i>Clinical Journal of Oncology Nursing<\/i>, <b>8<\/b>, 401-405.","key":"E00013","DOI":"10.1188\/04.CJON.401-405"},{"doi-asserted-by":"crossref","unstructured":"Doss, D.S. (2006). Advances in oral therapy in the treatment of multiple myeloma. <i>Clinical Journal of Oncology Nursing<\/i>, <b>10<\/b>, 514-520.","key":"E00014","DOI":"10.1188\/06.CJON.514-520"},{"doi-asserted-by":"crossref","unstructured":"Fonseca, R., & Stewart, A.K. (2007). Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. <i>Molecular Cancer Therapeutics<\/i>, <b>6<\/b>, 802-810.","key":"E00015","DOI":"10.1158\/1535-7163.MCT-06-0620"},{"doi-asserted-by":"crossref","unstructured":"Hideshima, T., Chauhan, D., Richardson, P., & Anderson, K.C. (2005). Identification and validation of novel therapeutic targets for multiple myeloma. <i>Journal of Clinical Oncology<\/i>, <b>23<\/b>, 6345-6350.","key":"E00016","DOI":"10.1200\/JCO.2005.05.024"},{"doi-asserted-by":"crossref","unstructured":"Hirsch, J. (2007). Risk of thrombosis with lenalidomide and its prevention with aspirin. <i>Chest<\/i>, <b>131<\/b>, 275-277.","key":"E00017","DOI":"10.1378\/chest.06-2360"},{"doi-asserted-by":"crossref","unstructured":"Morrison, R. (2006). Venous thromboembolism: Scope of the problem and the nurse's role in risk assessment and prevention. <i>Journal of Vascular Nursing<\/i>, <b>24<\/b>(3), 82-90.","key":"E00018","DOI":"10.1016\/j.jvn.2006.05.002"},{"unstructured":"Multiple Myeloma Research Foundation. (2006). Myeloma treatments: Revlimid\u00ae. Retrieved March 25, 2007, from <a target=\"_blank\" href='http:\/\/www.multiplemyeloma.org\/treatments\/3.08.02.html'>http:\/\/www.multiplemyeloma.org\/treatments\/3.08.02.html<\/a>","key":"E00019"},{"doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V. (2005). Thalidomide therapy and deep venous thrombosis in multiple myeloma. <i>Mayo Clinic Proceedings<\/i>, <b>80<\/b>, 1549-1551.","key":"E00020","DOI":"10.4065\/80.12.1549"},{"doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P.R. (2006). Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology<\/i>, <b>24<\/b>, 431-436.","key":"E00021","DOI":"10.1200\/JCO.2005.03.0221"},{"doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, S., et al. (2005). Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. <i>Blood<\/i>, <b>106<\/b>, 4050-4053.","key":"E00022","DOI":"10.1182\/blood-2005-07-2817"},{"doi-asserted-by":"crossref","unstructured":"Richardson, P.G., Blood, E., Mitsiades, C.S., Jagannath, S., Zeldenrust, S.R., Alsina, M., et al. (2006). A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. <i>Blood<\/i>, <b>108<\/b>, 3458-3464.","key":"E00023","DOI":"10.1182\/blood-2006-04-015909"},{"doi-asserted-by":"crossref","unstructured":"Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003). Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. <i>Journal of Clinical Oncology<\/i>, <b>21<\/b>, 16-19.","key":"E00024","DOI":"10.1200\/JCO.2003.03.139"},{"doi-asserted-by":"crossref","unstructured":"Zangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A.V., et al. (2001). Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. <i>Blood<\/i>, <b>98<\/b>, 1614-1615.","key":"E00025","DOI":"10.1182\/blood.V98.5.1614"},{"doi-asserted-by":"crossref","unstructured":"Zangari, M., Barologie, B., Anaissie, E., Saghafifar, F., Eddlemon, P., Jacobson, J., et al. (2004). Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. <i>British Journal of Haematology<\/i>, <b>126<\/b>, 715-721.","key":"E00026","DOI":"10.1111\/j.1365-2141.2004.05078.x"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/R5266K1G71G43236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:57Z","timestamp":1763754657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/11\/6\/multiple-myeloma-and-treatment-related-thromboembolism-oncology"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,1]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12,1]]}},"alternative-id":["R5266K1G71G43236"],"URL":"https:\/\/doi.org\/10.1188\/07.cjon.847-851","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2007,12,1]]}}}